CN101568332A - 抑制血管生成及治疗血管生成相关疾病的方法 - Google Patents

抑制血管生成及治疗血管生成相关疾病的方法 Download PDF

Info

Publication number
CN101568332A
CN101568332A CNA2006800561122A CN200680056112A CN101568332A CN 101568332 A CN101568332 A CN 101568332A CN A2006800561122 A CNA2006800561122 A CN A2006800561122A CN 200680056112 A CN200680056112 A CN 200680056112A CN 101568332 A CN101568332 A CN 101568332A
Authority
CN
China
Prior art keywords
colchicine
nab
composition
compositions
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800561122A
Other languages
English (en)
Chinese (zh)
Inventor
N·P·德塞
V·特里优
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Inc USA filed Critical Abraxis Bioscience Inc USA
Publication of CN101568332A publication Critical patent/CN101568332A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2006800561122A 2006-08-31 2006-08-31 抑制血管生成及治疗血管生成相关疾病的方法 Pending CN101568332A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/034365 WO2008027055A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Publications (1)

Publication Number Publication Date
CN101568332A true CN101568332A (zh) 2009-10-28

Family

ID=37763804

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800561122A Pending CN101568332A (zh) 2006-08-31 2006-08-31 抑制血管生成及治疗血管生成相关疾病的方法

Country Status (9)

Country Link
EP (1) EP2056812A1 (de)
JP (1) JP2010502603A (de)
CN (1) CN101568332A (de)
AU (1) AU2006347740A1 (de)
BR (1) BRPI0622006A2 (de)
CA (1) CA2662140A1 (de)
IL (1) IL197276A0 (de)
MX (1) MX2009002054A (de)
WO (1) WO2008027055A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132927A (zh) * 2014-03-27 2016-11-16 因德纳有限公司 无定形形式的硫代秋水仙碱衍生物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3470071A1 (de) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Brustkrebstherapie auf basis des hormonrezeptorstatus mit nanopartikel mit taxan
EP2131821B1 (de) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoteilchen mit rapamycin und albumin als anti-krebs-mittel
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
EP2515930A4 (de) * 2009-12-21 2013-04-10 Tty Biopharm Co Ltd Verfahren und zusammensetzungen im zusammenhang mit reduzierter met-phosphorylierung durch aus leukozyten gewonnenes chemotaxin 2 in tumorzellen
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (de) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Verfahren zur behandlung von karzinomen
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
WO2013042684A1 (ja) * 2011-09-20 2013-03-28 国立大学法人熊本大学 リポ蛋白を用いた神経疾患予防・治療剤ならびに神経疾患予防・治療方法
EP3560486A1 (de) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Verwendung von polymeren hilfsstoffen zum gefriertrocknen oder gefrieren von partikeln
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (de) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Verfahren zur behandlung von lungenkrebs
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
KR20120068035A (ko) * 2002-12-09 2012-06-26 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
CA2509365C (en) * 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US6825236B2 (en) * 2003-04-14 2004-11-30 California Pacific Medical Center Colchicine derivatives
ITMI20040164A1 (it) * 2004-02-03 2004-05-03 Indena Spa Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132927A (zh) * 2014-03-27 2016-11-16 因德纳有限公司 无定形形式的硫代秋水仙碱衍生物

Also Published As

Publication number Publication date
WO2008027055A1 (en) 2008-03-06
MX2009002054A (es) 2009-05-01
IL197276A0 (en) 2009-12-24
CA2662140A1 (en) 2008-03-06
JP2010502603A (ja) 2010-01-28
EP2056812A1 (de) 2009-05-13
AU2006347740A1 (en) 2008-03-06
BRPI0622006A2 (pt) 2011-12-20

Similar Documents

Publication Publication Date Title
US20080280987A1 (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CN101568332A (zh) 抑制血管生成及治疗血管生成相关疾病的方法
AU2019202037B2 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
AU2013370955B2 (en) Nanoparticle compositions of albumin and paclitaxel
ES2243744T3 (es) Inhibidores de integrina para el tratamiento de enfermedades de los ojos.
ES2315312T3 (es) Procedimiento y composiciones para el tratamiento de enfermedades del ojo.
Khan et al. Ocular drug delivery: introduction and fundamental concept
CN111801094B (zh) 包含苯并吡喃衍生物或其药学上可接受的盐的溶液形式的滴眼剂
Jani et al. Ocular Drug Delivery Systems
Berillo et al. Review of recent advances in the use of drug delivery systems in ophthalmology
KR20090057074A (ko) 혈관형성 억제 및 혈관형성 관련 질환 치료 방법
Kim et al. Ocular permeation enhancers
Zhang et al. Nanoparticles for ocular drug delivery
TW200810745A (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
Patel et al. Nanotechnology in Ocular Drug Delivery
Ramesh Ocular barriers and ocular drug delivery: Bridging the gap using nanomicelles as drug carriers
US20190275001A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
KR20220122647A (ko) 망막모세포종의 치료를 위한 약제학적 조성물, 제형 및 방법
Kwatra et al. Routes of Ocular Drug Delivery-Conventional vs. Novel Routes
Shende et al. Unveiling the potential of drug delivery systems for tyrosine kinase inhibitors in the treatment of neovascular eye diseases
HK1241281A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
HK1241281B (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091028